GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (ASX:RCE) » Definitions » Valuation Rank

Recce Pharmaceuticals (ASX:RCE) Valuation Rank


View and export this data going back to 2016. Start your Free Trial

What is Recce Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Recce Pharmaceuticals Valuation Rank Related Terms

Thank you for viewing the detailed overview of Recce Pharmaceuticals's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Recce Pharmaceuticals (ASX:RCE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (ASX:RCE) » Definitions » Valuation Rank
Comparable Companies
ASX:BIT ASX:ALA ASX:DXB ASX:PIQ ASX:OCC ASX:ADO ASX:SPL ASX:PTX ASX:ACW ASX:RAC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
R9Q:Germany
Address
180 George Street, Level 23, Salesforce Tower, Sydney, NSW, AUS, 2000
Website
https://www.recce.com.au
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. It operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat the diseases caused by various bacterias namely Sepsis, Helicobacter Pylori, Escherichia coli, Pseudomonas aeruginosa, and others.